Bristol-Myers Squibb's Baraclude to Dominate the Hepatitis B Virus Market through 2015

WALTHAM, Mass., April 17 /PRNewswire-FirstCall/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Bristol-Myers Squibb's Baraclude will dominate the hepatitis B virus market through 2015. According to the new report entitled Coping with the Rise in Drug Resistance: A Hepatitis B Virus Study, Baraclude outperforms current therapies in efficacy and safety.

"In clinical trials, Baraclude has proved to be more efficacious in reducing viral load, which is the key end point influencing physicians' prescribing decisions," said Kaitlyn Sullivan, associate analyst at Decision Resources. "Also, Baraclude also more effectively reduces liver fibrosis and inflammation than the other therapies currently on the market, and the agent is less prone to viral resistance than GlaxoSmithKline's Epivir."

Most therapies in the pipeline for the treatment of hepatitis B virus do not have clinical profiles that can compete with Baraclude's efficacy and safety profiles.

About Coping with the Rise in Drug Resistance: A Hepatitis B Virus Study

Coping with the Rise in Drug Resistance: A Hepatitis B Virus Study covers the current and future state of the hepatitis B virus market. The report includes the following:

  -- More than 3,000 physician responses that define drug attributes that
     drive prescription now and in the future.
    -- Clinical end point tradeoffs that are most influential to physicians.
    -- Areas of unmet need with highest potential.
    -- Benchmark trial results for specific drug opportunities.
    -- Patient share potential for emerging therapies and target product
       profiles.
  -- Decision Resources proprietary analysis of commercial factors that
     accelerate or constrain a drug's market potential.
    -- Promotion: DTC spend, detailing intensity.
    -- Reimbursement: formulary tier, prior approval restriction, quantity
       limits.
    -- Labeling: black box warnings, approved patient segments,
       contraindications.
    -- Competition: order of entry, pricing, generic entry, pipeline sales
       forecast.
    -- Medical practice: decision trees, treating physician type, line of
       therapy.
  -- Comparisons of the key clinical attributes of current and emerging
     therapies in the areas of efficacy, safety, and delivery.
  -- Analysis and supporting data that identifies the clinical "Gold
     Standard" now and over the next ten years.
  -- Key insights as to which clinical end points have the greatest
     influence on physician decision-making.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:
  Elizabeth Marshall
  Decision Resources, Inc.
  781-296-2563
  emarshall@dresources.com